Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus HC 1.
COR-OTICIN vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Unknown
1-2 drops in each affected ear twice daily for 7 days.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
2–4 hours (terminal); prolonged in renal impairment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid